Arcus Biosciences, Inc. (RCUS) shareholders
Close on Nov 17, 2026Market cap $2.09BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 31,424,760 | 24.70% | 13D (active) amendment | Aug 5, 2026 |
| BlackRock, Inc. | 12,736,927 | 10.40% | 13G (passive) amendment | Dec 31, 2025 |
| Steven A. Cohen Joint filing with Point72 Asset Management, L.P. (5.50%), Point72 Capital Advisors, Inc. (5.50%) | 5,831,099 | 5.50% | 13G (passive) | May 12, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RCUS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 31,424,760 | 24.68% | $968.83M | – | 58.76% |
| BlackRock, Inc. | 16,416,249 | 12.89% | $506.11M | +1,189,774 | 0.01% |
| State Street Corp | 6,029,484 | 4.74% | $185.89M | +616,583 | 0.01% |
| Wellington Management Group Llp | 5,895,448 | 4.63% | $181.76M | −194,068 | 0.03% |
| Suvretta Capital Management, LLC | 4,776,423 | 3.75% | $147.26M | −254,570 | 2.69% |
| Vanguard Portfolio Management LLC | 4,475,528 | 3.51% | $137.98M | +203,472 | 0.01% |
| FMR LLC | 4,049,757 | 3.18% | $124.85M | +2,884,505 | 0.01% |
| Vanguard Capital Management LLC | 3,888,346 | 3.05% | $119.88M | +31,621 | 0.00% |
| Citadel Advisors LLC | 3,135,057 | 2.46% | $96.65M | +1,805,122 | 0.01% |
| Woodline Partners LP | 3,007,798 | 2.36% | $92.73M | −770,000 | 0.29% |
| Geode Capital Management, LLC | 2,448,749 | 1.92% | $75.51M | +196,382 | 0.00% |
| Siren, L.L.C. | 2,420,430 | 1.90% | $74.62M | −586,647 | 1.51% |
| Fisher Asset Management, LLC | 2,139,396 | 1.68% | $65.96M | −51,008 | 0.02% |
| Marshall Wace, Llp | 1,945,088 | 1.53% | $59.97M | −1,816,349 | 0.05% |
| Samlyn Capital, LLC | 1,547,182 | 1.22% | $47.70M | −361,230 | 0.78% |
| Dimensional Fund Advisors LP | 1,434,320 | 1.13% | $44.22M | +8,097 | 0.01% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,419,533 | 1.11% | $43.76M | −235,221 | 0.04% |
| Goldman Sachs Group Inc | 1,387,566 | 1.09% | $42.78M | +387,780 | 0.00% |
| Soleus Capital Management, L.P. | 1,168,738 | 0.92% | $36.03M | +716,755 | 1.24% |
| Sofinnova Investments, Inc. | 945,690 | 0.74% | $29.16M | +22,604 | 1.51% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 230 | 123M | 96.3% | 46 / 87 | 63 / 24 | 13M | 9M |
| Q1 2026 | 211 | 119M | 93.5% | 38 / 81 | 57 / 33 | 19M | 13M |
| Q4 2025 | 209 | 121M | 95.4% | 48 / 94 | 39 / 27 | 30M | 9M |
| Q3 2025 | 190 | 101M | 79.1% | 30 / 65 | 61 / 24 | 8M | 7M |
| Q2 2025 | 185 | 100M | 78.4% | 26 / 84 | 52 / 26 | 11M | 8M |
| Q1 2025 | 186 | 97M | 76.4% | 32 / 99 | 29 / 31 | 19M | 6M |
| Q4 2024 | 186 | 84M | 65.9% | 25 / 61 | 67 / 24 | 37M | 7M |
| Q3 2024 | 187 | 53M | 41.9% | 22 / 69 | 70 / 26 | 16M | 4M |
| Q2 2024 | 193 | 52M | 41.0% | 43 / 62 | 63 / 21 | 6M | 8M |
| Q1 2024 | 172 | 55M | 42.9% | 19 / 61 | 59 / 31 | 8M | 7M |
| Q4 2023 | 185 | 54M | 42.3% | 26 / 63 | 67 / 25 | 7M | 5M |
| Q3 2023 | 187 | 53M | 41.5% | 31 / 54 | 72 / 23 | 4M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
254 funds held RCUS in Q2 2026, 64% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of RCUS | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 5,229,079 | 4.11% | $161.21M | 0.14% | Jun 30, 2026 |
| Vanguard Health Care Fund | 3,445,827 | 2.71% | $97.14M | 0.25% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,798,199 | 2.20% | $86.27M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,587,788 | 2.03% | $79.78M | 0.74% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,296,136 | 1.80% | $70.79M | 0.09% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,008,565 | 0.79% | $31.09M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,000,539 | 0.79% | $30.85M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 978,275 | 0.77% | $27.58M | 0.08% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 852,700 | 0.67% | $21.61M | 0.41% | May 31, 2026 |
| Fidelity Small Cap Growth Fund | 809,070 | 0.64% | $22.81M | 0.26% | Jul 31, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 796,159 | 0.63% | $24.55M | 0.15% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 648,605 | 0.51% | $20.00M | 0.13% | Jun 30, 2026 |
| iShares Biotechnology ETF | 593,218 | 0.47% | $18.29M | 0.20% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 579,068 | 0.45% | $17.85M | 0.04% | Jun 30, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 572,430 | 0.45% | $14.51M | 0.25% | May 29, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Terry J. Rosen | Chief Executive Officer, Director | 5,670,279 | 4.45% | Jan 26, 2026 |
| Alexander Azoy | Chief Accounting Officer | 39,581 | 0.03% | Aug 24, 2026 |
| Juan C. Jaen | President | 1,200,799 | 0.94% | Jul 13, 2026 |
| Carolyn C. Tang | General Counsel | 184,607 | 0.14% | Jun 12, 2026 |
| II Robert C. Goeltz | Chief Financial Officer | 84,161 | 0.07% | May 12, 2026 |
| Richard Markus | Chief Medical Officer | 89,647 | 0.07% | Jan 26, 2026 |
| Jennifer Jarrett | Chief Operating Officer | 224,024 | 0.18% | Jan 26, 2026 |
| Dimitry SA Nuyten | Chief Medical Officer | 87,518 | 0.07% | Dec 17, 2024 |
| Patrick Machado | Director | 44,300 | 0.03% | Jun 12, 2026 |
| Nicole Lambert | Director | 43,000 | 0.03% | Jun 12, 2026 |
| Antoni Ribas | Director | 52,853 | 0.04% | Jun 12, 2026 |
| David L. Lacey | Director | 76,652 | 0.06% | Jun 12, 2026 |
| Andrew J. Perlman | Director | 48,325 | 0.04% | Jun 12, 2026 |
| Kathryn E. Falberg | Director | 176,406 | 0.14% | Jun 12, 2026 |
| Yasunori Kaneko | Director | 957,955 | 0.75% | Jun 12, 2026 |
| Dietmar Berger | Director | 0 | – | Feb 10, 2025 |
| Gilead Sciences, Inc. | 10% owner | 31,424,760 | 24.68% | Feb 20, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Alexander Azoy Chief Accounting Officer | Aug 21, 2026 | Sale(10b5-1 plan) | −2,827 | $30.00 | $84.81K | 39,581 |
| Alexander Azoy Chief Accounting Officer | Aug 21, 2026 | Option exercise | +2,827 | $15.44 | $43.65K | 42,408 |
| Juan C. Jaen President | Jul 10, 2026 | Sale(10b5-1 plan) | −19,799 | $28.61 | $566.45K | 822,508 |
| Juan C. Jaen President | Jul 10, 2026 | Sale(10b5-1 plan) | −268 | $29.40 | $7.88K | 822,240 |
| Juan C. Jaen President | Jul 9, 2026 | Sale(10b5-1 plan) | −48,502 | $30.05 | $1.46M | 842,307 |
| Juan C. Jaen President | Jun 24, 2026 | Sale(10b5-1 plan) | −6,431 | $29.66 | $190.74K | 890,809 |
| Juan C. Jaen President | Jun 23, 2026 | Sale(10b5-1 plan) | −14,067 | $27.69 | $389.52K | 898,937 |
| Juan C. Jaen President | Jun 23, 2026 | Sale(10b5-1 plan) | −1,697 | $28.06 | $47.62K | 897,240 |
| Juan C. Jaen President | Jun 22, 2026 | Sale(10b5-1 plan) | −9,236 | $27.03 | $249.65K | 913,004 |
| David L. Lacey Director | Jun 11, 2026 | Award | +5,700 | – | – | 76,652 |
| Yasunori Kaneko Director | Jun 11, 2026 | Award | +5,700 | – | – | 25,700 |
| Antoni Ribas Director | Jun 11, 2026 | Award | +5,700 | – | – | 44,300 |
| Kathryn E. Falberg Director | Jun 11, 2026 | Award | +5,700 | – | – | 44,300 |
| Patrick Machado Director | Jun 11, 2026 | Award | +5,700 | – | – | 44,300 |
| Carolyn C. Tang General Counsel | Jun 11, 2026 | Option exercise | +34,090 | $2.57 | $87.61K | 184,607 |
| Nicole Lambert Director | Jun 11, 2026 | Award | +5,700 | – | – | 43,000 |
| Andrew J. Perlman Director | Jun 11, 2026 | Award | +5,700 | – | – | 48,325 |
| Alexander Azoy Chief Accounting Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −2,562 | $25.77 | $66.02K | 39,581 |
| II Robert C. Goeltz Chief Financial Officer | May 11, 2026 | Sale(10b5-1 plan) | −7,763 | $25.63 | $198.97K | 84,161 |
| Juan C. Jaen President | Jan 23, 2026 | Award | +31,000 | – | – | 377,012 |
| Jennifer Jarrett Chief Operating Officer | Jan 23, 2026 | Award | +31,000 | – | – | 224,024 |
| II Robert C. Goeltz Chief Financial Officer | Jan 23, 2026 | Award | +24,000 | – | – | 91,924 |
| Carolyn C. Tang General Counsel | Jan 23, 2026 | Award | +24,000 | – | – | 148,734 |
| Alexander Azoy Chief Accounting Officer | Jan 23, 2026 | Award | +21,050 | – | – | 39,581 |
| Terry J. Rosen Chief Executive Officer, Director | Jan 23, 2026 | Award | +79,000 | – | – | 2,236,409 |
| Richard Markus Chief Medical Officer | Jan 23, 2026 | Award | +24,000 | – | – | 89,647 |
| Terry J. Rosen Chief Executive Officer, Director | Jan 8, 2026 | Gift | −35,000 | – | – | 2,157,409 |
| Juan C. Jaen President | Jan 5, 2026 | Sale(10b5-1 plan) | −100 | $23.20 | $2.32K | 922,240 |
| Juan C. Jaen President | Jan 5, 2026 | Sale(10b5-1 plan) | −29,670 | $21.34 | $633.16K | 924,393 |
| Juan C. Jaen President | Jan 5, 2026 | Sale(10b5-1 plan) | −2,053 | $22.34 | $45.86K | 922,340 |
| II Robert C. Goeltz Chief Financial Officer | Dec 31, 2025 | Sale(10b5-1 plan) | −6,552 | $23.38 | $153.19K | 67,924 |
| Terry J. Rosen Chief Executive Officer, Director | Dec 30, 2025 | Gift | −2,400 | – | – | 2,192,409 |
| Alexander Azoy Chief Accounting Officer | Dec 18, 2025 | Sale(10b5-1 plan) | −4,343 | $22.25 | $96.63K | 18,531 |
| Richard Markus Chief Medical Officer | Dec 17, 2025 | Sale(10b5-1 plan) | −4,494 | $22.16 | $99.59K | 65,647 |
| Carolyn C. Tang General Counsel | Dec 17, 2025 | Sale(10b5-1 plan) | −6,810 | $22.16 | $150.91K | 124,734 |
| Juan C. Jaen President | Dec 17, 2025 | Sale(10b5-1 plan) | −9,983 | $22.16 | $221.22K | 346,012 |
| Terry J. Rosen Chief Executive Officer, Director | Dec 17, 2025 | Sale(10b5-1 plan) | −25,744 | $22.16 | $570.49K | 2,194,809 |
| II Robert C. Goeltz Chief Financial Officer | Dec 17, 2025 | Sale(10b5-1 plan) | −5,960 | $22.16 | $132.07K | 74,476 |
| Jennifer Jarrett Chief Operating Officer | Dec 17, 2025 | Sale(10b5-1 plan) | −9,983 | $22.16 | $221.22K | 193,024 |
| Alexander Azoy Chief Accounting Officer | Dec 17, 2025 | Sale(10b5-1 plan) | −2,113 | $22.16 | $46.82K | 22,874 |
| Antoni Ribas Director | Dec 16, 2025 | Gift | −5,050 | – | – | 38,600 |
| Richard Markus Chief Medical Officer | Dec 16, 2025 | Sale(10b5-1 plan) | −5,052 | $21.88 | $110.54K | 70,141 |
| Carolyn C. Tang General Counsel | Dec 16, 2025 | Sale(10b5-1 plan) | −7,658 | $21.88 | $167.56K | 131,544 |
| Juan C. Jaen President | Dec 16, 2025 | Sale(10b5-1 plan) | −11,225 | $21.88 | $245.60K | 355,995 |
| Terry J. Rosen Chief Executive Officer, Director | Dec 16, 2025 | Sale(10b5-1 plan) | −28,947 | $21.88 | $633.36K | 2,220,553 |
| II Robert C. Goeltz Chief Financial Officer | Dec 16, 2025 | Sale(10b5-1 plan) | −6,702 | $21.88 | $146.64K | 80,436 |
| Jennifer Jarrett Chief Operating Officer | Dec 16, 2025 | Sale(10b5-1 plan) | −11,225 | $21.88 | $245.60K | 203,007 |
| Alexander Azoy Chief Accounting Officer | Dec 16, 2025 | Sale(10b5-1 plan) | −2,376 | $21.88 | $51.99K | 24,987 |
| Juan C. Jaen President | Dec 4, 2025 | Sale(10b5-1 plan) | −82,997 | $24.71 | $2.05M | 954,063 |
| Alexander Azoy Chief Accounting Officer | Nov 26, 2025 | Option exercise | +1,900 | $13.33 | $25.33K | 29,263 |
| Alexander Azoy Chief Accounting Officer | Nov 26, 2025 | Sale(10b5-1 plan) | −1,900 | $26.00 | $49.40K | 27,363 |
| II Robert C. Goeltz Chief Financial Officer | Nov 26, 2025 | Sale(10b5-1 plan) | −5,000 | $25.00 | $125.00K | 87,138 |
| Juan C. Jaen President | Nov 18, 2025 | Sale(10b5-1 plan) | −5,050 | $19.75 | $99.74K | 1,037,060 |
| Juan C. Jaen President | Nov 17, 2025 | Sale(10b5-1 plan) | −7,836 | $20.71 | $162.28K | 1,042,110 |
| Juan C. Jaen President | Nov 17, 2025 | Sale(10b5-1 plan) | −37,114 | $20.23 | $750.82K | 1,049,946 |
| Jennifer Jarrett Chief Operating Officer | Nov 7, 2025 | Option exercise | +50,291 | $1.23 | $61.86K | 264,523 |
| Jennifer Jarrett Chief Operating Officer | Nov 7, 2025 | Sale(10b5-1 plan) | −50,291 | $18.97 | $954.02K | 214,232 |
| Juan C. Jaen President | Oct 30, 2025 | Sale(10b5-1 plan) | −4,314 | $20.32 | $87.66K | 1,087,060 |
| Juan C. Jaen President | Oct 29, 2025 | Sale(10b5-1 plan) | −800 | $22.04 | $17.63K | 1,091,374 |
| Juan C. Jaen President | Oct 29, 2025 | Sale(10b5-1 plan) | −29,365 | $21.53 | $632.23K | 1,092,174 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Arcus Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 8,867 shares on Aug 26, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Alexander Azoy Officer | Aug 21, 2026 | 2,827 | $83.45K | Aug 21, 2026 | Exercise of Stock Options |
| Juan C. Jaen Officer | Jul 9, 2026 | 25,000 | $749.00K | Jul 9, 2026 | Acquired as compensation -- Restricted Stock Units |
| Juan C. Jaen Officer | Jun 24, 2026 | 50,000 | $1.44M | Jun 24, 2026 | Acquired as compensation -- Restricted Stock Units |
| Juan C. Jaen Officer | Jun 22, 2026 | 25,000 | $680.75K | Jun 22, 2026 | Acquired as compensation -- Restricted Stock Units |
| Alexander Azoy Officer | Jun 1, 2026 | 2,562 | $64.92K | Jun 1, 2026 | Employee Stock Purchase Plan |
| II Robert C. Goeltz Officer | May 11, 2026 | 7,763 | $198.97K | May 11, 2026 | Restricted Stock Unit |
| Jennifer Jarrett Officer | May 6, 2026 | 77,793 | $1.91M | May 6, 2026 | Stock Option Exercise |
| Jennifer Jarrett Officer | Apr 23, 2026 | 53,826 | $1.36M | Apr 23, 2026 | Stock Option Exercise |
| Jennifer Jarrett Officer | Apr 8, 2026 | 70,000 | $1.58M | Apr 8, 2026 | Stock Option Exercise |
| Juan C. Jaen Officer | Jan 5, 2026 | 31,823 | $692.79K | Jan 5, 2026 | Acquired from issuer in private transaction |
| II Robert C. Goeltz Officer | Dec 31, 2025 | 6,552 | $153.19K | Dec 31, 2025 | Restricted Stock Unit |
| Alexander Azoy Officer | Dec 18, 2025 | 4,343 | $96.76K | Dec 18, 2025 | Restricted Stock Units |
| Jennifer Jarrett Officer | Dec 15, 2025 | 22,000 | $481.80K | Dec 16, 2025 | Vesting of restricted stock granted 3/8/2022 |
| II Robert C. Goeltz Officer | Dec 15, 2025 | 14,000 | $306.60K | Dec 16, 2025 | Vesting of restricted stock granted 3/8/2022 |
| Alexander Azoy Officer | Dec 15, 2025 | 5,000 | $109.50K | Dec 16, 2025 | Vesting of restricted stock granted 3/8/2022 |
See a number that looks wrong?